Department of Rheumatology, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, The Netherlands.
Ann Rheum Dis. 2010 Jun;69(6):1110-6. doi: 10.1136/ard.2009.116384. Epub 2010 May 3.
The presence of anti-citrullinated protein antibodies (ACPA) is a powerful predictive factor for the development and progression of rheumatoid arthritis (RA). The ACPA response has been shown to consist of various isotypes, but the consequences of differences in isotype distribution have not been extensively investigated.
To investigate the relationship between ACPA isotypes, disease progression and radiological outcome.
ACPA isotypes were determined in sera of anti-cyclic citrullinated peptide 2-positive patients by enzyme-linked immunosorbent assay (ELISA). To investigate whether the ACPA response continues to evolve during disease development, the ACPA isotype profile during progression of undifferentiated arthritis (UA) to RA was studied. The association of disease progression with ACPA isotype use was assessed using long-term radiographic follow-up data from patients with RA in two independent cohorts.
The ACPA isotype distribution did not expand during disease progression from UA to RA, but was relatively stable over time. In both RA cohorts, the baseline ACPA isotype profile was a significant predictor of disease severity, with more isotypes indicating a higher risk of radiographic damage (odds ratio for every additional isotype: 1.4 (95% CI 1.1 to 1.9) p<0.001). ACPA isotypes supplied additional prognostic information to ACPA status alone, even after correction for other predictive factors.
The magnitude of the ACPA isotype profile at baseline reflects the risk of future radiographic damage. These results indicate that the presence and the constitution of the ACPA response are relevant to the disease course of RA.
抗瓜氨酸化蛋白抗体 (ACPA) 的存在是类风湿关节炎 (RA) 发生和进展的有力预测因素。已经表明 ACPA 反应由各种同型组成,但同型分布差异的后果尚未得到广泛研究。
研究 ACPA 同型与疾病进展和放射学结果之间的关系。
通过酶联免疫吸附试验 (ELISA) 测定抗环瓜氨酸肽 2 阳性患者血清中的 ACPA 同型。为了研究 ACPA 反应是否在疾病发展过程中继续演变,研究了未分化关节炎 (UA) 向 RA 进展过程中的 ACPA 同型谱。使用来自两个独立队列的 RA 患者的长期放射学随访数据评估疾病进展与 ACPA 同型使用之间的关联。
从 UA 到 RA 的疾病进展过程中,ACPA 同型分布没有扩大,而是随着时间的推移相对稳定。在两个 RA 队列中,基线 ACPA 同型谱是疾病严重程度的显著预测因子,更多的同型表明放射学损害的风险更高(每增加一个同型的优势比:1.4(95%CI 1.1 至 1.9)p<0.001)。即使在对其他预测因素进行校正后,ACPA 同型也能提供额外的预后信息。
基线时 ACPA 同型谱的幅度反映了未来放射学损害的风险。这些结果表明 ACPA 反应的存在和组成与 RA 的疾病进程相关。